Pharma stocks dive 20-55% this year after ban on combination drugs
While Marksans Pharma has fallen 47% in 2016 so far, Wockhardt posted a decline of 38% and Pfizer 29%
Mumbai: The government ban on fixed dose combination (FDC) drugs has taken a toll on pharmaceuticals stocks, which saw a fall in the range of 20-50% year-to-date. Marksans Pharma Ltd has fallen 47% in 2016 so far, while Wockhardt Ltd posted a decline of 38% in its share price. Pfizer Ltd, another company which got affected with the FDC ban, saw its shares fall 29% year-to-date.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more